share_log

信達生物:澄清公告 - 授出受限制股份

INNOVENT BIO: CLARIFICATION ANNOUNCEMENT - GRANT OF RESTRICTED SHARES

香港交易所 ·  Apr 3 09:37
Summary by Moomoo AI
信達生物製藥有限公司(「信達生物」)於2024年4月3日發布澄清公告,修正了其於2024年3月24日所發布的關於向非關聯僱員授出受限制股份的公告中的錯誤。原公告中提到的受限制股份歸屬期分配比例有誤,正確的比例應為75%的股份將於2027年3月22日歸屬,餘下的25%將於2028年3月22日歸屬。此次澄清公告指出,之前公告中所述的每年三分之一股份歸屬的說法是由於書寫錯誤所致。除了歸屬期的更正外,原公告的其他資訊保持不變。
信達生物製藥有限公司(「信達生物」)於2024年4月3日發布澄清公告,修正了其於2024年3月24日所發布的關於向非關聯僱員授出受限制股份的公告中的錯誤。原公告中提到的受限制股份歸屬期分配比例有誤,正確的比例應為75%的股份將於2027年3月22日歸屬,餘下的25%將於2028年3月22日歸屬。此次澄清公告指出,之前公告中所述的每年三分之一股份歸屬的說法是由於書寫錯誤所致。除了歸屬期的更正外,原公告的其他資訊保持不變。
Sinda Biopharmaceuticals Limited (“Sinda Biologics”) issued a Clarification Notice on April 3, 2024, correcting errors in its announcement issued on March 24, 2024 regarding the granting of restricted shares to unrelated employees. The allocation ratio of restricted shares referred to in the original announcement is incorrect. The correct proportion should be 75% of the shares will be attributed on March 22, 2027, and the remaining 25% will be attributed on March 22, 2028. THIS CLARIFICATION ANNOUNCEMENT INDICATES THAT ONE-THIRD OF THE ANNUAL SHARE ATTRIBUTION DESCRIBED IN THE PRIOR ANNOUNCEMENT WAS DUE TO A CLERICAL ERROR. Other information in the original announcement remains unchanged, except for corrections to the attribution period.
Sinda Biopharmaceuticals Limited (“Sinda Biologics”) issued a Clarification Notice on April 3, 2024, correcting errors in its announcement issued on March 24, 2024 regarding the granting of restricted shares to unrelated employees. The allocation ratio of restricted shares referred to in the original announcement is incorrect. The correct proportion should be 75% of the shares will be attributed on March 22, 2027, and the remaining 25% will be attributed on March 22, 2028. THIS CLARIFICATION ANNOUNCEMENT INDICATES THAT ONE-THIRD OF THE ANNUAL SHARE ATTRIBUTION DESCRIBED IN THE PRIOR ANNOUNCEMENT WAS DUE TO A CLERICAL ERROR. Other information in the original announcement remains unchanged, except for corrections to the attribution period.
Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more